Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
Public ClinicalTrials.gov record NCT03736928. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
An interventional phase 2 study to evaluate safety and efficacy of AbobotulinumtoxinA treatment for glabellar lines
Study identification
- NCT ID
- NCT03736928
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 401 participants
Conditions and interventions
Conditions
Interventions
- AbobotulinumtoxinA dose level 1 or 2 Biological
- placebo Other
- AbobotulinumtoxinA dose 3 Biological
- AbobotulinumtoxinA dose 4 Biological
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 25, 2018
- Primary completion
- Dec 8, 2019
- Completion
- Aug 19, 2020
- Last update posted
- Aug 25, 2022
2018 – 2020
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Galderma Research Site | Encino | California | 91436 | — |
| Galderma Research Site | Manhattan Beach | California | 90266 | — |
| Galderma Research Site | Vista | California | 92083 | — |
| Galderma Research Site | Coral Gables | Florida | 33146 | — |
| Galderma Research Site | Chicago | Illinois | 60611 | — |
| Galderma Research Site | New Orleans | Louisiana | 70130 | — |
| Galderma Research Site | New York | New York | 10028 | — |
| Galderma Research Site | Chapel Hill | North Carolina | 27517 | — |
| Galderma Research Site | Charlotte | North Carolina | 28207 | — |
| Galderma Research Site | Mequon | Wisconsin | 53092 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03736928, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 25, 2022 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03736928 live on ClinicalTrials.gov.